ADC Therapeutics SA (ADCT) Form 8-K — Nov 9, 2026
ADC Therapeutics reported Q3 2026 net product revenue of $21.0 million, up 33% from $15.8 million a year ago, driven by volume growth for ZYNLONTA. Net loss narrowed to $25.3 million from $41.0 million. The company completed a strategic financial restructuring, including an $86.6 million PIPE led by Bain Capital Life Sciences, a $68.5 million reduction in senior secured loan principal, and elimination of a $150 million change-of-control payment — extending expected cash runway into 2029. Cash was $189.2 million at quarter-end, down from $261.3 million at the end of 2025, and the company carries a $249.2 million shareholder deficit.
Key figures
- Revenue
- 21006000
- Revenue Yoy
- 33% increase vs $15.8M in Q3 2025
- Total Assets
- 255863000
- Cash Position
- 189200000
- Pipe shares
- 12900000
- Pipe financing
- 86600000
- Warrant strike
- CHF 0.08
- Warrants issued
- 48000000
- Adjusted opex q3
- 32038000
- Cash dec 31 2025
- 261338000
- Net loss yoy change
- vs $41.0M in Q3 2025
- Loan principal reduction
- 68500000
- Loan principal remaining
- 50000000
- Nine month product revenue
- 59673000
- Deferred royalty obligation
- 303488000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.